Tecentriq Takes EU Lead In Triple-Negative Breast Cancer
Executive Summary
Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.
You may also be interested in...
India's SPARC Keeps Paclitaxel Ambition Burning For Now
A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.
England’s NICE Rejects Tecentriq In Triple-Negative Breast Cancer
NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-negative breast cancer.
Roche Wins Two French Early Access Programs In Breast Cancer
Roche's cancer drugs, Tecentriq (atezolizumab) and Kadcyla (trastuzumab emtansine), are the latest products to be granted French temporary use authorizations for new, as yet unapproved indications.